CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients

被引：20

作者：

Coto-Segura, Pablo ^{[1
,4
]}

Batalla, Ana ^{[1
]}

Gonzalez-Fernandez, Daniel ^{[1
]}

Gomez, Juan ^{[2
]}

Santos-Juanes, Jorge ^{[1
]}

Queiro, Ruben ^{[3
]}

Alonso, Belen ^{[2
]}

Iglesias, Sara ^{[2
]}

Coto, Eliecer ^{[2
,4
]}

机构：

[1] Hosp Univ Cent Asturias, Dermatol, Oviedo 33011, Spain

[2] Hosp Univ Cent Asturias, Genet Mol, Oviedo 33011, Spain

[3] Hosp Univ Cent Asturias, Reumatol, Oviedo 33011, Spain

[4] Univ Oviedo, Dept Med, Oviedo, Spain

来源：

INTERNATIONAL IMMUNOPHARMACOLOGY | 2015年 / 29卷 / 02期

关键词：

Psoriasis; CDKAL1; Gene polymorphism; Anti-TNF; CROHNS-DISEASE; RISK; ASSOCIATION; LOCI; RNA;

D O I：

10.1016/j.intimp.2015.11.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The heterogeneous response to anti-TNF biological drugs among Psoriasis (Psor) patients might be explained by gene variants linked to the risk for Psor. Common variants in the CDKAL1 gene have been associated with the risk of developing Psor. Our hypothesis was that these variants could also influence the response to anti-TNFs among Psor-patients. A reduction of at least 75% in the Psoriasis area and severity index (PASI 75) at week 24 was considered a positive response to treatment. A total of 116 patients (78 responders and 38 non-responders) were genotyped for the CDKAL1 rs6908425, rs4712523, rs111739077, and rs77152992 (p.P409L) single nucleotide polymorphisms. Allele and genotype frequencies differed between the two response groups, with the highest difference for the rs6908425: CC homozygotes were significantly more common among responders (72% vs. 45%; p = 0.005; OR = 3.14, 95%CI = 1.40-7.05). In conclusion, our data suggested that CDKAL1 gene variants have a significant effect on the response to anti-TNF therapies among Psor patients. If confirmed on other large cohorts of patients, the genotyping of these variants might help to predict the biological response. (C) 2015 Elsevier B.V. All rights reserved.

引用

页码：947 / 949

页数：3

共 15 条

[1] Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis [J].

Chiu, H. -Y. ;

Wang, T. -S. ;

Chan, C. -C. ;

Cheng, Y. -P. ;

Lin, S. -J. ;

Tsai, T. -F. .

BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (05) :1181-1188

[2]

LEE FI, 1990, AM J GASTROENTEROL, V85, P962

[3] Further Genetic Evidence for Three Psoriasis-Risk Genes: ADAM33, CDKAL1, and PTPN22 [J].

Li, Yonghong ;

Liao, Wilson ;

Chang, Monica ;

Schrodi, Steven J. ;

Bui, Nam ;

Catanese, Joseph J. ;

Poon, Annie ;

Matsunami, Nori ;

Callis-Duffin, Kristina P. ;

Leppert, Mark F. ;

Bowcock, Anne M. ;

Kwok, Pui-Yan ;

Krueger, Gerald G. ;

Begovich, Ann B. .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2009, 129 (03) :629-634

[4] A cautionary tale: the non-causal association between type 2 diabetes risk SNP, rs7756992, and levels of non-coding RNA, CDKAL1-v1 [J].

Locke, Jonathan M. ;

Wei, Fan-Yan ;

Tomizawa, Kazuhito ;

Weedon, Michael N. ;

Harries, Lorna W. .

DIABETOLOGIA, 2015, 58 (04) :745-748

[5] Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene [J].

Nair, RP ;

Stuart, PE ;

Nistor, I ;

Hiremagalore, R ;

Chia, NVC ;

Jenisch, S ;

Weichenthal, M ;

Abecasis, GR ;

Lim, HW ;

Christophers, E ;

Voorhees, JJ ;

Elder, JT .

AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 78 (05) :827-851

[6] Differential contribution of CDKAL1 variants to psoriasis, Crohn's disease and type II diabetes [J].

Quaranta, M. ;

Burden, A. D. ;

Griffiths, C. E. M. ;

Worthington, J. ;

Barker, J. N. ;

Trembath, R. C. ;

Capon, F. .

GENES AND IMMUNITY, 2009, 10 (07) :654-658

[7] Long-range gene regulation links genomic type 2 diabetes and obesity risk regions to HHEX, SOX4, and IRX3 [J].

Ragvin, Anja ;

Moro, Enrico ;

Fredman, David ;

Navratilova, Pavla ;

Drivenes, Oyvind ;

Engstrom, Par G. ;

Alonso, M. Eva ;

de la Calle Mustienesg, Elisa ;

Gomez Skarmeta, Jose Luis ;

Tavares, Maria J. ;

Casares, Fernando ;

Manzanares, Miguel ;

van Heyningen, Veronica ;

Molven, Anders ;

Njolstad, Pal R. ;

Argenton, Francesco ;

Lenhard, Boris ;

Becker, Thomas S. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (02) :775-780

[8] A variant in CDKAL1 influences insulin response and risk of type 2 diabetes [J].

Steinthorsdottir, Valgerdur ;

Thorleifsson, Gudmar ;

Reynisdottir, Inga ;

Benediktsson, Rafn ;

Jonsdottir, Thorbjorg ;

Walters, G. Bragi ;

Styrkarsdottir, Unnur ;

Gretarsdottir, Solveig ;

Emilsson, Valur ;

Ghosh, Shyamali ;

Baker, Adam ;

Snorradottir, Steinunn ;

Bjarnason, Hjordis ;

Ng, Maggie C. Y. ;

Hansen, Torben ;

Bagger, Yu ;

Wilensky, Robert L. ;

Reilly, Muredach P. ;

Adeyemo, Adebowale ;

Chen, Yuanxiu ;

Zhou, Jie ;

Gudnason, Vilmundur ;

Chen, Guanjie ;

Huang, Hanxia ;

Lashley, Kerrie ;

Doumatey, Ayo ;

So, Wing-Yee ;

Ma, Ronald C. Y. ;

Andersen, Gitte ;

Borch-Johnsen, Knut ;

Jorgensen, Torben ;

van Vliet-Ostaptchouk, Jana V. ;

Hofker, Marten H. ;

Wijmenga, Cisca ;

Christiansen, Claus ;

Rader, Daniel J. ;

Rotimi, Charles ;

Gurney, Mark ;

Chan, Juliana C. N. ;

Pedersen, Oluf ;

Sigurdsson, Gunnar ;

Gulcher, Jeffrey R. ;

Thorsteinsdottir, Unnur ;

Kong, Augustine ;

Stefansson, Kari .

NATURE GENETICS, 2007, 39 (06) :770-775

[9] Biologics in psoriasis: A quick reference guide [J].

Thomas, VD ;

Yang, FC ;

Kvedar, JC .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 53 (02) :346-351

[10] Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms [J].

Warren, R. B. ;

Smith, R. L. ;

Campalani, E. ;

Eyre, S. ;

Smith, C. H. ;

Barker, J. N. W. N. ;

Worthington, J. ;

Griffiths, C. E. M. .

BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (02) :438-441

← 1 2 →